Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates

Follow the latest updates of the outbreak on our timeline.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Pfizer has confirmed that the company has initiated efforts to advance its potential antiviral therapies and also develop a vaccine against Covid-19.

The company is in discussions with its existing partner BioNTech to create a potential mRNA coronavirus vaccine.

Earlier this month, Pfizer identified several antiviral compounds, already in development, with potential to block coronaviruses.

Pfizer chairman and CEO Dr Albert Bourla said: “Many companies, including Pfizer, are working to develop antiviral therapies to help infected patients fight this emerging virus as well as new vaccines to prevent infection and halt the further spread of this disease.

“Pfizer is working to advance our own potential antiviral therapies and is engaged with BioNTech on a potential mRNA coronavirus vaccine. We are committed to working as one team across the industry to harness our scientific expertise, technical skills and manufacturing capabilities to combat this evolving crisis.”

The company is adopting a five-point strategy to fight the ongoing Covid-19 pandemic globally.

Companies and researchers are developing cell-based assays, screening, serological assays and translational models to assess potential therapies and vaccines for coronavirus.

The tools developed by Pfizer will be available on an open-source platform. The company will also share its data and insights with other companies in real-time.

Pfizer has a dedicated team of virologists, biologists, chemists, clinicians, epidemiologists, vaccine experts and pharmaceutical scientists, among other experts, to work only on combating the outbreak.

The team is working to rapidly discover and develop therapies and vaccines.

Pfizer will also share its clinical development and regulatory expertise with smaller biotech firms in order to support the most promising candidates against Covid-19.

The company will also provide its manufacturing capabilities to rapidly scale and deploy an approved coronavirus therapy or vaccine.